Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar set for September 20, 2022, at 4:30 p.m. ET. The company released a video showcasing its AIMIGo technology, a credit card-sized ECG device for remote heart attack detection, which is expected to receive FDA clearance by year-end. This technology aims to enhance heart attack detection capabilities outside medical settings, expediting treatment and reducing healthcare costs. Key executives will discuss recent announcements and milestones during the webinar.
HeartBeam, Inc. (NASDAQ: BEAT) has received a patent for its innovative 12-lead ECG patch monitor, which allows for the detection of acute coronary syndrome and cardiac arrhythmia outside medical settings. This technology enhances traditional ECG diagnostics, contributing to a projected global market of $4.8B by 2030. The new patent complements existing patents, bolstering HeartBeam's intellectual property portfolio and offering potential advancements in cardiac care diagnostics.
HeartBeam, Inc. (NASDAQ: BEAT) has announced a virtual roadshow webinar on September 20, 2022, at 4:30 p.m. ET. During this event, a new video showcasing the HeartBeam AIMIGo technology for heart attack detection will be unveiled. While the AIMI and AIMIGo technologies are pending FDA clearance, they aim to enhance heart attack detection outside of medical settings. The webinar will feature CEO Branislav Vajdic and other executives discussing the company’s milestones and 510(k) application progress. Access the webinar via the provided link.
HeartBeam, Inc. (NASDAQ: BEAT) has submitted a 510(k) application to the US FDA for its HeartBeam AIMI™ technology, aimed at improving heart attack diagnosis. This step is crucial for the company's commercialization efforts within a $500 million market. With over 18 million individuals affected by coronary artery disease in the US, and heart attacks occurring every 40 seconds, the technology aims to enhance the diagnostic process in emergency departments. CEO Branislav Vajdic expressed optimism regarding FDA clearance and anticipated a full commercial roll-out in Q1 2023.
HeartBeam, Inc. (NASDAQ: BEAT) reported its Q2 2022 financial and operational results, highlighting significant advancements towards FDA submissions for its HeartBeam AIMI™ software platform and AIMIGo™ telehealth solution. The company plans to submit the AIMI platform for FDA clearance around August 15, 2022, and aims for AIMIGo submission in Q4 2022. Q2 net loss was $3.5 million, with cash reserves at $9.3 million. HeartBeam expanded its target patient population by including unstable angina, enhancing the platform's clinical validation study scope.
HeartBeam, Inc. (NASDAQ: BEAT) announced the appointment of Ken Persen as Chief Technology Officer, bringing over 25 years of experience in digital healthcare and cardiac devices. Persen will lead the technology strategy and development of the HeartBeam AIMI™ and AIMIGo™ platforms, enhancing the company's innovative ECG telemedicine technology. This appointment aims to improve the management of heart attack symptoms outside medical institutions, addressing a significant market need.
Summary not available.
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on August 11, 2022 at 4:30 p.m. Eastern Time to discuss its second quarter results, which ended June 30, 2022. The call will also cover recent announcements and key milestones for 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will present and facilitate a Q&A session. Investors can access the call via dial-in or webcast. A replay will be available after the call until November 11, 2022.
HeartBeam, Inc. (NASDAQ: BEAT) announced an expansion of its clinical validation study to include a broader patient population for its emergency department software technology. The decision follows the recent AHA guidelines and aims to include unstable angina patients, which may enhance heart attack detection. HeartBeam plans to file a 510K submission by August 15, 2022, which remains unaffected by the Telehealth product's timeline, scheduled for Q4 2022. This expanded scope aligns with their goal of improving cardiovascular diagnosis.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare innovator, will present at the LD Micro Invitational XII Conference from June 7-9, 2022, in Westlake Village, CA. CFO Rick Brounstein and CBO Jon Hunt, PhD, will host 25-minute meetings and deliver a presentation on June 7 at 4:00 pm ET. HeartBeam specializes in proprietary ECG telemedicine technology aimed at improving heart attack detection outside medical institutions. This significant advancement addresses the high-risk cardiovascular patient population's needs. For more details, visit ir.heartbeam.com.